Research location

New Haven

Connecticut, United States

Published trials1,930

Site observations2,130

Linked trials published1,930

Page2 / 39

Research activity in New Haven

Connecticut, United States

CureCurrent currently publishes aggregate city-level research activity for this location: 1,930 trials and 2,130 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in New Haven

1,930 linked trials · page 2 of 39

Saci Nivo Rela for TNBCNCT06963905 · 2025-12-29 · 1 site observation

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid TumorsNCT07222267 · 2025-12-11 · 1 site observation

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderNCT06793397 · 2025-12-10 · 1 site observation

FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine TherapyNCT06917313 · 2025-12-05 · 1 site observation

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)NCT07218146 · 2025-11-30 · 1 site observation

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung CancerNCT07155174 · 2025-11-25 · 1 site observation

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's DiseaseNCT07174310 · 2025-11-24 · 1 site observation

Shared Decision Making to Treat Or Prevent (STOP) HIV in Criminal Legal Involved Populations (R33)NCT07223398 · 2025-11-24 · 1 site observation

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell CarcinomasNCT07217171 · 2025-11-13 · 1 site observation

New Mechanisms of ObesityNCT06768827 · 2025-11-13 · 1 site observation

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM StudyNCT06769126 · 2025-11-06 · 1 site observation

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerNCT07085767 · 2025-11-03 · 1 site observation

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid TumorsNCT07182149 · 2025-10-30 · 1 site observation

Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBCNCT07066189 · 2025-10-17 · 1 site observation

M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid TumorsNCT07166601 · 2025-10-10 · 1 site observation

A Trial Comparing High-Flow Nasal Cannula Versus Noninvasive Ventilation on Reintubation and Post-Extubation Respiratory Failure in High-Risk Patients With Systolic Heart FailureNCT06671015 · 2025-10-04 · 1 site observation

Exploring Water-free Sodium StorageNCT06872645 · 2025-10-03 · 1 site observation

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) AmyloidosisNCT07207811 · 2025-10-02 · 1 site observation

Circulating Tumor DNANCT06923527 · 2025-09-30 · 1 site observation

This Protocol is a Sub-study Under the PPMI Program. It is a Longitudinal, Single-center Study to Assess the Performance of [18F]AV-133 Imaging Using High and Standard Resolution PET in Individuals Enrolled With Parkinson's Disease (PD) for up to 12 Months.NCT07830654 · 2025-09-25 · 1 site observation

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)NCT07111520 · 2025-09-22 · 1 site observation

A Comparative Performance Study Between High and Standard Resolution Positron Emission Tomography Camera Using [18F] AV-133 in Prodromal Parkinson's DiseaseNCT07809438 · 2025-09-18 · 1 site observation

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabNCT06876714 · 2025-09-17 · 1 site observation

T1CARE: A Trial of a Novel Intervention to Address Social Determinants of Health in Young Adults With Type 1 DiabetesNCT07059806 · 2025-09-05 · 2 site observations

Home-based Oral Glucose Tolerance Test for Type 1 Diabetes ScreeningNCT07155252 · 2025-08-26 · 1 site observation

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerNCT06982521 · 2025-08-26 · 1 site observation

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid TumorsNCT07169734 · 2025-08-26 · 1 site observation

ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid TumorsNCT06998407 · 2025-08-20 · 1 site observation

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid TumorsNCT07090499 · 2025-08-20 · 3 site observations

A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)NCT07196501 · 2025-08-18 · 1 site observation

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant TumorsNCT07070232 · 2025-08-12 · 1 site observation

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 DiabetesNCT07088068 · 2025-08-06 · 1 site observation

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.NCT07062965 · 2025-08-05 · 1 site observation

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLCNCT07098988 · 2025-08-01 · 1 site observation

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)NCT07033494 · 2025-07-16 · 1 site observation

Building and Sustaining Exercise Habits for Adults With Type 1 DiabetesNCT06967701 · 2025-07-10 · 1 site observation

Simulation Trial of Telemedical Support for ParamedicsNCT06441760 · 2025-07-10 · 1 site observation

Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine TherapyNCT06953882 · 2025-07-09 · 1 site observation

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease StudiesNCT07177352 · 2025-07-02 · 1 site observation

Trial of Trastuzumab Deruxtecan in Previously Treated HER2NCT06750484 · 2025-06-20 · 1 site observation

A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate CancerNCT06990880 · 2025-06-12 · 1 site observation

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid TumorsNCT06993844 · 2025-06-10 · 1 site observation

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)NCT07038343 · 2025-06-04 · 1 site observation

A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's DiseaseNCT06976268 · 2025-05-28 · 1 site observation

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)NCT06616584 · 2025-05-22 · 1 site observation

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)NCT06952504 · 2025-05-22 · 1 site observation

Regulation of Brain Glucose Metabolism in Type 1 DiabetesNCT05317455 · 2025-05-13 · 1 site observation

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)NCT06925737 · 2025-05-13 · 1 site observation

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantNCT06563895 · 2025-05-12 · 1 site observation

Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's DiseaseNCT07020026 · 2025-05-12 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.